Vical highlights DNA vaccine technology at medical meeting

By Lisa Kerner

Charlotte, N.C., June 7 - Vical Inc. researchers presented data from several of the company's DNA vaccine development programs at the annual meeting of the American Society of Gene Therapy.

In a series of recent animal studies, electroporation was shown to enhance antibody production against an encoded cytomegalovirus antigen and enhances anthrax lethal toxin neutralizing antibody production after vaccination.

In recent animal studies with the company's anthrax vaccine candidate, a DNA vaccine showed potential to induce a memory immune response for which conventional assays may not be accurate predictors of protection; and may provide protective immunity.

San Diego-based Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.